COMMUNIQUÉS West-GlobeNewswire

-
Better Choice Company Announces Pet CBD Research & Development Partnership in Israel with CannaSoul
07/06/2019 -
TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019
07/06/2019 -
AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers
07/06/2019 -
GBT Announces New Employment Inducement Grants
07/06/2019 -
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions
07/06/2019 -
Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting
07/06/2019 -
Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
07/06/2019 -
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
07/06/2019 -
Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
07/06/2019 -
Rockwell Medical Announces Adjournment of Annual Meeting of Shareholders
07/06/2019 -
Nightstar Therapeutics PLC Completion of Acquisition by Biogen
07/06/2019 -
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
07/06/2019 -
Saniona publishes prospectus relating to the rights issue
07/06/2019 -
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology
07/06/2019 -
Acarix participates on the Redeye Growth Day, Monday 10 June 2019
07/06/2019 -
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
07/06/2019 -
Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
07/06/2019 -
Paul Hudson succèdera à Olivier Brandicourt comme Directeur Général
07/06/2019 -
Novartis announces new leader of Pharmaceuticals Business Unit
07/06/2019
Pages